P. Lyne

发表

Self-organizing molecular field analysis: a tool for structure-activity studies.

W. Richards, D. Robinson, P. Winn, 1999, Journal of medicinal chemistry.

Insights into Chorismate Mutase Catalysis from a Combined QM/MM Simulation of the Enzyme Reaction

W. Richards, P. Lyne, A. Mulholland, 1995 .

Identification of compounds with nanomolar binding affinity for checkpoint kinase-1 using knowledge-based virtual screening.

J. Wendoloski, P. Lyne, S. Ashwell, 2004, Journal of medicinal chemistry.

Inhibitors of checkpoint kinases: from discovery to the clinic.

P. Lyne, J. Janetka, S. Ashwell, 2007, Current opinion in drug discovery & development.

COMBINED QUANTUM AND MOLECULAR MECHANICAL STUDY OF DNA CROSS-LINKING BY NITROUS ACID

A. Elcock, P. Lyne, A. Mulholland, 1995 .

Discovery of a novel class of 2-ureido thiophene carboxamide checkpoint kinase inhibitors.

V. Oza, P. Lyne, J. Janetka, 2008, Bioorganic & medicinal chemistry letters.

Modelling the catalytic reaction in human aldose reductase

W. Richards, P. Várnai, P. Lyne, 1999, Proteins.

Identification of amidoheteroaryls as potent inhibitors of mutant (V600E) B-Raf kinase with in vivo activity.

David A. Scott, P. Lyne, L. Drew, 2009, Bioorganic & medicinal chemistry letters.

Selectivity of stearate-modified carbon paste electrodes for dopamine and ascorbic acid

P. Lyne, R. O'Neill, 1989 .

Stearate-modified carbon paste electrodes for detecting dopamine in vivo: decrease in selectivity caused by lipids and other surface-active agents.

P. Lyne, R. O'Neill, 1990, Analytical chemistry.

Molecular Orbital Analysis of the Intermediates and Products Generated by the Photooxidation of Iron Pentacarbonyl

P. Lyne, D. Mingos, A. J. Downs, 1993 .

Determination of the pKaof the 2‘-Hydroxyl Group of a Phosphorylated Ribose: Implications for the Mechanism of Hammerhead Ribozyme Catalysis

M. Karplus, P. Lyne, 2000 .

Discovery of (2R)-N-[3-[2-[(3-methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a potent and selective Janus Kinase 1 (JAK1) inhibitor.

C. Chuaqui, A. Ferguson, P. Lyne, 2020, Journal of medicinal chemistry.

Discovery of 2,6-disubstituted pyrazine derivatives as inhibitors of CK2 and PIM kinases.

A. Ferguson, P. Lyne, N. Larsen, 2018, Bioorganic & medicinal chemistry letters.

oligonucleotide in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.

J. Nemunaitis, R. Kurzrock, M. Jo, 2018 .

MYELOID NEOPLASIA AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates ef ﬁ cacy in preclinical models of acute myeloid leukemia

L. Platanias, P. Lyne, R. Stone, 2014 .

On Evaluating Molecular-Docking Methods for Pose Prediction and Enrichment Factors. [J. Chem. Inf. Model. 46, 401-415 (2006)]

Jin Li, Hongming Chen, Fabrizio Giordanetto, 2008, J. Chem. Inf. Model..

Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer.

David A. Scott, Edward W. Tate, J. Dry, 2018, Cancer research.

Molecular structure and gas-phase reactivity of zileuton and its N-dehydroxylated metabolite: two-layered ONIOM calculations

W. Richards, P. Lyne, M. Remko, 2000 .

Discovery of AZ0108, an orally bioavailable phthalazinone PARP inhibitor that blocks centrosome clustering.

David A. Scott, S. Kazmirski, A. Ferguson, 2015, Bioorganic & medicinal chemistry letters.

Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinases.

David A. Scott, Bin Wang, Yongxin Han, 2008, Journal of medicinal chemistry.

Investigation of the trans influence in transition-metal nitride complexes

D. Michael P. Mingos, P. Lyne, D. Mingos, 1995 .

Pyridyl and thiazolyl bisamide CSF-1R inhibitors for the treatment of cancer.

David A. Scott, P. Lyne, B. Aquila, 2008, Bioorganic & medicinal chemistry letters.

Structure and Property Based Design of Pyrazolo[1,5-a]pyrimidine Inhibitors of CK2 Kinase with Activity in Vivo.

C. Chuaqui, P. Lyne, N. Larsen, 2013, ACS medicinal chemistry letters.

A theoretical study of Te64+ and Te4S42+

P. Lyne, D. Mingos, T. Ziegler, 1992 .

The effects of back-bonding to phosphines on the trans influence in [Mo(NH)Cl3(PR3)2]0,±1 (R H, Me and F)

D. Michael P. Mingos, P. Lyne, D. Mingos, 1994 .

A Theoretical Study of Te4+ 6 and Te4S2+ 4.

P. Lyne, D. Mingos, T. Ziegler, 1992 .

Molecular structure, gas-phase acidity and basicity of N-hydroxyurea

W. Richards, P. Lyne, M. Remko, 1999 .

AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia.

Allan Wu, Paul D Lyne, Xiaolan Zheng, 2014, Blood.

Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring.

Paul D Lyne, P. Lyne, M. Lamb, 2006, Journal of medicinal chemistry.

Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS

P. Lyne, B. Monia, D. Blakey, 2017, Science Translational Medicine.

BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors

G. Mills, A. Dulak, Wei Zhao, 2018, PloS one.

STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.

J. Nemunaitis, R. Kurzrock, M. Jo, 2018, Journal of Immunotherapy for Cancer.

Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer

S. Barry, G. Kar, P. Lyne, 2022, Journal for ImmunoTherapy of Cancer.

Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas.

J. Breed, V. Oza, P. Lyne, 2012, Journal of medicinal chemistry.

Discovery and optimization of a novel series of potent mutant B-Raf(V600E) selective kinase inhibitors.

Allan Wu, Edward Hennessy, Jon Read, 2013, Journal of medicinal chemistry.

Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases.

A. Ferguson, P. Lyne, E. Keeton, 2012, Bioorganic & medicinal chemistry letters.

On Evaluating Molecular-Docking Methods for Pose Prediction and Enrichment Factors

Jin Li, Hongming Chen, Fabrizio Giordanetto, 2006, J. Chem. Inf. Model..

Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity.

E. Hennessy, V. Oza, P. Lyne, 2015, Journal of medicinal chemistry.

Modulating the strength of hydrogen bond acceptors to achieve low Caco2 efflux for oral bioavailability of PARP inhibitors blocking centrosome clustering.

David A. Scott, S. Kazmirski, P. Lyne, 2016, Bioorganic & medicinal chemistry letters.

Structure-based virtual screening: an overview.

Paul D Lyne, P. Lyne, 2002, Drug discovery today.

Volatiles from the foliage of soybean, Glycine max, and lima bean, Phaseolus lunatus: their behavioral effects on the insects Trichoplusia ni and Epilachna varivestis

P. Lyne, Shaohua Liu, D. Norris, 1989 .

Abstract 5561: High-affinity antisense oligonucleotides targeting Foxp3 inhibit immunosuppressive function of regulatory T-cells and produce antitumor effects in syngeneic tumor models

S. Barry, P. Lyne, A. Macleod, 2018, Clinical research.

AZD1208, a Novel, Potent and Selective Pan PIM Kinase Inhibitor, Demonstrates Efficacy in Models of Acute Myeloid Leukemia

P. Lyne, Jeffrey L. Brown, E. Keeton, 2011 .

Molecular modeling of the GM‐CSF and IL‐3 receptor complexes

P. Bamborough, P. Lyne, W. Richards, 1995, Protein science : a publication of the Protein Society.

Discovery and Optimization of a Novel Series of Highly Selective JAK1 Kinase Inhibitors.

C. Chuaqui, A. Ferguson, P. Lyne, 2018, Journal of medicinal chemistry.

Discovery of heterocyclic sulfonamides as sphingosine 1-phosphate receptor 1 (S1P1) antagonists.

E. Hennessy, L. Ronco, V. Oza, 2015, Bioorganic & medicinal chemistry letters.

Potent and Selective Inhibitors of CK2 Kinase Identified through Structure-Guided Hybridization.

C. Chuaqui, P. Lyne, Nancy Su, 2012, ACS medicinal chemistry letters.

Lead Hopping Using SVM and 3D Pharmacophore Fingerprints

David A. Cosgrove, Paul D. Lyne, Jamal C. Saeh, 2005, J. Chem. Inf. Model..

AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies

G. Mills, A. Dulak, A. Rabow, 2016, Molecular Cancer Therapeutics.

Abstract 979: Discovery of the JAK1 selective kinase inhibitor AZD4205

C. Chuaqui, P. Lyne, N. Grimster, 2017 .

Adventures in Scaffold Morphing: Discovery of Fused Ring Heterocyclic Checkpoint Kinase 1 (CHK1) Inhibitors.

J. Breed, P. Lyne, J. Janetka, 2018, Journal of Medicinal Chemistry.

Molecular structure of tetrakis(tert-butylimido)osmium(VIII), determined in the gas phase by electron diffraction

H. Robertson, G. Wilkinson, P. Lyne, 1994 .

Synthesis and evaluation of triazolones as checkpoint kinase 1 inhibitors.

Jon Read, Mei Su, J. Breed, 2012, Bioorganic & medicinal chemistry letters.

Discovery of a novel class of triazolones as checkpoint kinase inhibitors--hit to lead exploration.

J. Breed, V. Oza, P. Lyne, 2010, Bioorganic & medicinal chemistry letters.

A Hybrid QM−MM Potential Employing Hartree−Fock or Density Functional Methods in the Quantum Region

Milan Hodošček, Martin Karplus, M. Karplus, 1999 .

Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors.

Bin Wang, Yongxin Han, P. Lyne, 2012, ACS medicinal chemistry letters.

Potent and Selective CK2 Kinase Inhibitors with Effects on Wnt Pathway Signaling in Vivo.

C. Chuaqui, Emma L. Jenkins, A. Ferguson, 2016, ACS medicinal chemistry letters.

A partial model of the erythropoietin receptor complex

P. Lyne, W. Richards, Justin A. Caravella, 1996, Proteins.

1135OPhase 1b/2 Study (SCORES) assessing safety, tolerability, and preliminary anti-tumor activity of durvalumab plus AZD9150 or AZD5069 in patients with advanced solid malignancies and squamous cell carcinoma of the head and neck (SCCHN)

P. Lyne, D. Hong, W. William, 2017 .

Linking molecular characteristics to the pharmacological response of a panel of cancer cell lines to the BRAF inhibitor, AZ628

P. Lyne, L. Drew, B. Aquila, 2007 .

Abstract 5580: Preclinical pharmacodynamics and antitumor activity of AZD4635, a novel adenosine 2A receptor inhibitor that reverses adenosine mediated T cell suppression

James D. Clarke, M. Congreve, J. Mason, 2017 .

Computer Simulation of Biochemical Reactions with QM–MM Methods

P. Lyne, Own Walsh, 2001 .

Discovery of a novel class of 2-ureido thiophene carboxamide checkpoint kinase inhibitors.

P. Lyne, J. Janetka, S. Ashwell, 2008, Bioorganic & medicinal chemistry letters.

A phase I dose escalation, safety and pharmacokinetic (PK) study of AZD5312 (IONIS-ARRx), a first-in-class Generation 2.5 antisense oligonucleotide targeting the androgen receptor (AR)

Suzanne F. Jones, P. Elvin, H. Burris, 2016 .

Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinases.

David A. Scott, Bin Wang, Yongxin Han, 2008, Journal of medicinal chemistry.